Words for clinical notes
Search 5,131 terms by clinical wording, everyday description, or note example.
| Word | Plain-English search cue | Original note example | SOAP section | Writing task |
|---|---|---|---|---|
carbamazepine epoxide | active carbamazepine metabolite measured separately by some assays | The carbamazepine epoxide result is listed separately from the parent level. | Objective | Drug levels - named analytes and exposure reports |
censored result | inequality reported instead of an exact number | The censored result is recorded as less than 2 mg/L. | Objective | Drug levels - analyte, specimen and reporting |
chromatography | separation technique used before detection in some assays | The assay used liquid chromatography before detection. | Objective | Drug levels - analyte, specimen and reporting |
clozapine | antipsychotic whose concentration may be reported with its metabolite | The laboratory reports clozapine and norclozapine as separate analytes. | Objective | Drug levels - named analytes and exposure reports |
corrected concentration | value adjusted mathematically using stated assumptions | The corrected concentration was calculated and is identified separately from the measured value. | Objective | Drug levels - analyte, specimen and reporting |
critical result | value meeting the reporting laboratory's critical notification policy | The critical result was phoned to the covering clinician. | Objective | Drug levels - analyte, specimen and reporting |
critical result read-back | recipient repeats an urgent result to confirm accurate communication | Document the critical result read-back with the recipient, time, analyte and units. | Plan | Documentation, follow-up and transitions |
cyclosporine | immunosuppressant monitored using a specified timed sampling strategy | The cyclosporine report specifies whether the order was for a predose or two-hour sample. | Objective | Drug levels - named analytes and exposure reports |
detection limit | lowest amount distinguishable from background under stated conditions | The report lists the assay's detection limit alongside the qualitative result. | Objective | Drug levels - analyte, specimen and reporting |
digoxin | cardiac glycoside for which dose-to-draw time affects concentration interpretation | The digoxin result was collected two hours after the reported dose. | Objective | Drug levels - named analytes and exposure reports |
dilution factor | number used to account for dilution in measurement | The reference laboratory documented the applied dilution factor. | Objective | Drug levels - analyte, specimen and reporting |
estimated concentration | value inferred from a model or calculation | The report labels the value as an estimated concentration. | Objective | Drug levels - analyte, specimen and reporting |
ethanol | alcohol measured in a specified specimen and unit | The blood ethanol result is recorded in the units used by the laboratory. | Objective | Drug levels - named analytes and exposure reports |
everolimus | mTOR inhibitor with indication-specific monitoring considerations | The everolimus trough is documented with the transplant team's stated target. | Objective | Drug levels - named analytes and exposure reports |
flucytosine | antifungal monitored using drug- and protocol-specific sampling | The flucytosine sample is documented with its exact postdose interval. | Objective | Drug levels - named analytes and exposure reports |
free concentration | amount of drug measured in the unbound fraction | The phenytoin free concentration is reported separately from total drug. | Objective | Drug levels - analyte, specimen and reporting |
gentamicin | aminoglycoside monitored using regimen-specific sampling | The gentamicin result is paired with the infusion end time and draw time. | Objective | Drug levels - named analytes and exposure reports |
hydroxyitraconazole | active itraconazole metabolite measured in some drug assays | The laboratory lists hydroxyitraconazole separately on the antifungal drug report. | Objective | Drug levels - named analytes and exposure reports |
icterus index | instrument estimate of bilirubin-related specimen discoloration | The icterus index exceeded the assay's stated interference threshold. | Objective | Drug levels - analyte, specimen and reporting |
| test that uses antibody recognition | The outside concentration was measured by immunoassay. | Objective | Drug levels - analyte, specimen and reporting | |
interval monitoring | planned repeat measurement during ongoing care | Specify the analyte and timing for interval monitoring. | Plan | Monitoring actions, escalation and result communication |
itraconazole | azole antifungal for which drug and active metabolite may be reported | The itraconazole and hydroxyitraconazole results are reported individually. | Objective | Drug levels - named analytes and exposure reports |
laboratory flag | annotation applied by the reporting laboratory | A high laboratory flag accompanies the numerical result. | Objective | Drug levels - analyte, specimen and reporting |
lamotrigine | antiseizure medicine for which a concentration may be compared with an individual baseline | The lamotrigine result is listed with the patient's earlier stable value. | Objective | Drug levels - named analytes and exposure reports |
levetiracetam | antiseizure medicine measurable in serum or plasma under an appropriate assay | The levetiracetam concentration was collected at a documented interval after the dose. | Objective | Drug levels - named analytes and exposure reports |